Corcept’s (CORT) Multibagger Momentum Builds on Relacorilant and Expanding Commercial Footprint

Core Insights - Corcept Therapeutics Inc. has revised its 2025 revenue guidance to $850-$900 million, down from $900-$950 million, but management remains confident in growth due to an expanded sales force, new pharmacy partnerships, and pipeline progress [1][2] - The potential of relacorilant is emphasized, with a projected annual revenue of $3-$5 billion in hypercortisolism alone, and a PDUFA date set for December 30, 2025 [2] - The company has established a dedicated oncology division to prepare for the commercialization of relacorilant, which is expected to launch quickly if approved [2][3] - Additional studies are being conducted in various cancer settings and other indications, with a second pharmacy expected to enhance revenue growth starting Q4 2023 [3] Financial Performance - Corcept's stock has doubled over the past year, with analysts projecting another 100% return over the next 12 months, all assigning a Buy or equivalent rating [4] - The company is focused on treating severe endocrinologic, oncologic, metabolic, and neurologic disorders through cortisol modulation [4]